Fast-Paced Growth in End-use Adoption to Propel Pulmonary Fibrosis Treatment Market Revenue Growth

21/mag/2020 16:47:51 persistencemarketresearch Contatta l'autore

Questo comunicato è stato pubblicato più di 30 giorni fa. Le informazioni su questa pagina potrebbero non essere attendibili.

New York City, United States -- The change during the COVID-19 pandemic has overhauled our dependence on pattern setting developments, for instance, expanded reality, computer generated reality, and the Healthcare web of things. The unfulfilled cash related targets are persuading the relationship to grasp robotization and forefront advancements to stay ahead in the market competition. Associations are utilizing this open entryway by recognizing step by step operational needs and showing robotization in it to make an automated structure as far as might be feasible.


Globally, increasing diagnosis rate for the pulmonary fibrosis is expected to drive the growth of the pulmonary fibrosis treatment market. According to the latest research by the company, the global pulmonary fibrosis treatment market is projected to account for a market value of ~US$ 4.4 Bn by the end of 2029. The report also projects significant growth potential for the pulmonary fibrosis treatment market throughout the forecast period.

Increasing diagnosis rate of the pulmonary fibrosis due to enhanced understanding of the disease is the prime driver of the pulmonary fibrosis treatment market. Although the disease understanding and understanding of the associated symptoms has advanced immensely, misdiagnosis still remains as high as 40% in developed regions, potentially hampering the growth of the pulmonary fibrosis treatment market.

Get Sample Copy of Report @

Company Profiles:

  • Genentech, Inc.
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Alkem Laboratories Ltd.
  • Alniche Life Sciences Pvt Ltd
  • MHS Pharmaceuticals
  • Torrent Pharmaceuticals Ltd
  • Anthem Biopharma Pvt Ltd
  • Panacea Biotec
  • Zydus Healthcare Ltd
  • Nuper Therapeutics
  • Fresenius Kabi India Pvt Ltd.
  • Sun Pharmaceutical Industries Ltd

Increasing literature about the pulmonary fibrosis treatment, causes and increasing small and medium sized regional studies by universities, pulmonary fibrosis organizations are assisting to improve the overall awareness about the disease in the general population.

The similarities of symptoms of pulmonary fibrosis with other respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, etc. are the major impediments in the precise diagnosis of the disease delaying the pulmonary fibrosis treatment.

Get To Know Methodology of Report @

Combination Drug Therapies

Corticosteroids, coupled with immunosuppressants and chemotherapeutic agents, were the only treatment available for the pulmonary fibrosis till the drugs such fibrosis Ofev (nintedanib) and Esbriet (pirfenidone) approved for the pulmonary fibrosis treatment in 2014. 

Both drugs slow disease progression by slowing down the lung tissue scarring. Patients treated with monotherapy of these drugs or combination therapy of these drugs along with corticosteroids or immunosuppressants has given healthcare professionals pulmonary fibrosis treatment options for the effective management of the disease.

Various new therapies are being evaluated by pharmaceutical and biopharmaceutical companies for the possible pulmonary fibrosis treatment.

Orphan drug designation reduces drug development cost considerably in turn encouraging pharmaceutical and biopharmaceutical companies to develop drugs for the treatment of rare diseases such as pulmonary fibrosis. Companies that received the orphan drug designation for their products for pulmonary fibrosis treatment benefitted from protocol assistance, marketing authorization, financial incentives, and national incentives provided by the European Commission.

The FDA orphan drug designation programs offer a unique status to biologics and drugs intended to pulmonary fibrosis treatment, diagnose, and prevent diseases in the U.S. The FDA orphan drug designation offers an exclusivity period of seven-year marketing for competition and certain incentives including tax credits, federal grants, and a waiver of PDUFA filing fees.

Access Full Report @

In August 2019, Daewoong Pharmaceutical received orphan drug designation from UFDA for its DWN12088, oral IPF therapy.

The company has segmented the global pulmonary fibrosis treatment market based on the therapy type, indication, distribution channel, and region. In terms of revenue, the monotherapy segment by therapy type is expected to be a prominent segment in pulmonary fibrosis treatment market over the forecast period.

By indication, the idiopathic pulmonary fibrosis (IPF) segment of the pulmonary fibrosis treatment market is expected to generate highest revenue during the forecast period due to higher prevalence of the disease type. By distribution channel, the pulmonary fibrosis treatment market is expected to be dominated by the retail sales segment due to higher patient footfall.

By region, the North America pulmonary fibrosis treatment market is expected to be a prominent region in the global pulmonary fibrosis treatment market.

Report Highlights:

  • Shifting Industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size Recent industry trends
  • Key Competition landscape
  • Strategies of key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance

Explore Extensive Coverage of PMR`s Life Sciences & Transformational Health Landscape

Liquid Chromatographymass Spectroscopy Market – Liquid Chromatography-Mass Spectroscopy Segmented By Triple Quadrupole, Time of Flight, Quadrupole Technology in Clinical Testing, Environmental Testing, Forensic TestingFor More Information

Biopharmaceutical Market – Biopharmaceuticals Market Segmented By Monoclonal Antibodies, Recombinant Proteins, Granulocyte-Colony Stimulating Factor, Interferons, Recombinant Human Insulin, Erythropoietin, Vaccines, Growth Hormones, Purified Proteins Type for Metabolic Disorders, Oncology, Neurological Disorders, Cardiovascular Diseases, Inflammatory and Infectious DiseasesFor More Information

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMR’s collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish Kolte
Persistence Market Research
Address – 305 Broadway, 7th FloorNew York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales –
Website –

blog comments powered by Disqus è un servizio offerto da Factotum Srl